Literature DB >> 7989361

The mechanism of inactivation of human factor V and human factor Va by activated protein C.

M Kalafatis1, M D Rand, K G Mann.   

Abstract

The cleavage of human factor V and human factor Va by human activated protein C (APC) was analyzed in the absence and presence of phospholipid vesicles containing 75% phosphatidylcholine (PC) and 25% phosphatidylserine (PS). Membrane-bound human factor V (250 nM) is cleaved by APC (2.5 nM) to give M(r) = 200,000, 70,000, 45,000, and 30,000 fragments and an M(r) = 22/20,000 doublet. These fragments are released after four sequential cleavages of the membrane-bound procofactor at Arg306, Arg506, Arg679, and Lys994. No cofactor activity is observed following thrombin treatment of the membrane-bound APC-cleaved procofactor. In the absence of a membrane surface, no cleavage of factor V by APC is observed, and following thrombin activation factor Va retains full cofactor activity. Membrane-bound human factor Va (600 nM) loses more than 90% of its initial cofactor activity after 10 min of incubation with APC (10.9 nM), and virtually no cofactor activity is observed after 1 h of incubation. Under similar conditions but in the absence of PCPS vesicles, factor Va is cleaved but retains approximately 80% of its initial cofactor activity after 2 h of incubation with APC. In the presence of PCPS vesicles, the APC related loss of activity is correlated with cleavage of the heavy chain and appearance of fragments of M(r) = 45,000, 30,000, and of 28/26,000, and 22/20,000 doublets. These products correspond to three cleavages of the heavy chain (at Arg306, Arg506, and Arg679). Cleavage at Arg506 of factor Va precedes and appears to be required for cleavage at Arg306 and Arg679. In the absence of membrane, proteolysis at Arg506 produces an M(r) = 75,000 fragment which corresponds to the NH2-terminal portion of the human factor Va heavy chain (residues 1-506), and a carboxyl-terminal doublet of M(r) = 28/26,000 (residues 507-709) which is cleaved by APC at Arg679 to generate an M(r) = 22/20,000 doublet and an M(r) = 6,000 peptide. No cleavage of the light chain of the human cofactor is observed in the presence or absence of PCPS vesicles following 2 h of incubation with APC. Our data demonstrate that inactivation of human factor V and human factor Va only occurs in the presence of a membrane surface after cleavage at Arg306. However, while this cleavage site is exposed on membrane-bound human factor V, cleavage at Arg506 on the heavy chain of factor Va appears necessary for complete exposure of the cleavage site at Arg306.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989361

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  74 in total

1.  Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.

Authors:  Thomas J Cramer; John H Griffin; Andrew J Gale
Journal:  Pathophysiol Haemost Thromb       Date:  2010-05-22

2.  Autolysis loop restricts the specificity of activated protein C: analysis by FRET and functional assays.

Authors:  Shabir H Qureshi; Chandrashekhara Manithody; Jong-Sup Bae; Likui Yang; Alireza R Rezaie
Journal:  Biophys Chem       Date:  2008-02-25       Impact factor: 2.352

3.  The Journey of Protein S from an Anticoagulant to a Signaling Molecule.

Authors:  V S Pilli; William Plautz; Rinku Majumder
Journal:  JSM Biochem Mol Biol       Date:  2016-08-08

4.  Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.

Authors:  J Petäjä; J A Fernández; A Gruber; J H Griffin
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

5.  Gly197Arg mutation in protein C causes recurrent thrombosis in a heterozygous carrier.

Authors:  Yeling Lu; Hemant Giri; Bruno O Villoutreix; Qiulan Ding; Xuefeng Wang; Alireza R Rezaie
Journal:  J Thromb Haemost       Date:  2020-04-09       Impact factor: 5.824

6.  Polymorphisms in factor V and antithrombin III gene in recurrent pregnancy loss: a case-control study in Indian population.

Authors:  Amit Sharma; Teena Bhakuni; Ravi Ranjan; Ravi Kumar; Kamal Kishor; Vineet Kumar Kamal; Manoranjan Mahapatra; Mohamad Aman Jairajpuri; Renu Saxena
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

7.  Platelet protein S directly inhibits procoagulant activity on platelets and microparticles.

Authors:  Fabian Stavenuiter; Nicole F Davis; Erning Duan; Andrew J Gale; Mary J Heeb
Journal:  Thromb Haemost       Date:  2012-12-13       Impact factor: 5.249

8.  Correlation with Platelet Parameters and Genetic Markers of Thrombophilia Panel (Factor II g.20210G>A, Factor V Leiden, MTHFR (C677T, A1298C), PAI-1, β-Fibrinogen, Factor XIIIA (V34L), Glycoprotein IIIa (L33P)) in Ischemic Strokes.

Authors:  Sener Tasdemir; Haktan Bagis Erdem; Ibrahim Sahin; Lutfi Ozel; Gokhan Ozdemir; Recep Eroz; Abdulgani Tatar
Journal:  Neuromolecular Med       Date:  2016-03-07       Impact factor: 3.843

9.  Proteolysis of plasma-derived factor V following its endocytosis by megakaryocytes forms the platelet-derived factor V/Va pool.

Authors:  F Ayombil; S Abdalla; P B Tracy; B A Bouchard
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

10.  Variable contributions of basic residues forming an APC exosite in the binding and inactivation of factor VIIIa.

Authors:  Masahiro Takeyama; Jennifer M Wintermute; Chandrashekhara Manithody; Alireza R Rezaie; Philip J Fay
Journal:  Biochemistry       Date:  2013-03-22       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.